State Street SPDR S&P Biotech ETF
XBI
Updated: 24/09/2026, 03:42:13
SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.
No summaries found.
- Share price
- $155.20
- Market cap
- $8.11B
- Exchange
- AMEX
- Currency
- USD
- CEO
- N/A
- Employees
- N/A
- IPO date
- 06/02/2006
- Beta
- 1.1
- Last dividend
- $0.00
- Day range
- $154.44 – $162.68
- 52-week range
- $95.74 – $169.89
- 1-day performance
- -4.12%
- 1-year performance
- 62.11%
- Current drawdown (1Y)
- -8.65%
- CIK
- 0001064642
- CUSIP
- 78464A870
- ISIN
- US78464A8707
- Created
- 07/12/2025, 15:08:48
- Last update
- 24/09/2026, 03:42:13
Track State Street SPDR S&P Biotech ETF with an AI analyst
See which prediction-market events move XBI, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
‘Buying stuff like it's going out of fashion': Biotech M&A on track for best year since pre-Covid
CNBC • STOCK • 04/06/2026, 03:45:06
Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
Zacks Investment Research • STOCK • 27/05/2026, 09:20:34
SPDR S&P Biotech ETF (XBI) Price Forecast: Long-Term Breakout Fuels Biotech Strength
FXEmpire • STOCK • 08/05/2026, 19:07:54
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research • STOCK • 22/04/2026, 09:21:11
XBI vs. IBB: The Biotech ETF Showdown That Analysts Say Has a Clear Winner in 2026
24/7 Wall Street • STOCK • 07/04/2026, 12:20:10
This Biotech ETF Is Still Well Below Its 2021 Peak. Analysts Say That Is Exactly Why to Buy It.
24/7 Wall Street • STOCK • 03/04/2026, 12:17:41
XBI: Biotech M&A Has Been Hot, But Price Trends Have Cooled
Seeking Alpha • STOCK • 13/03/2026, 23:45:44
Should You Invest in the State Street SPDR S&P Biotech ETF (XBI)?
Zacks Investment Research • STOCK • 19/02/2026, 08:20:36